Follica

Follica is a private, clinical-stage biotech pioneering a regenerative medicine platform for dermatology, with a primary focus on androgenetic alopecia (pattern hair loss). The company's core technology involves a proprietary combination of epidermal disruption and topical drug formulations to reprogram skin cells and generate new hair follicles. Having progressed its lead program into later-stage clinical trials, Follica is positioned to address a significant unmet need in the multi-billion dollar hair restoration market. Its platform also holds potential for broader applications in skin regeneration and wound healing.

Proprietary Regenerative Dermatology Platform combining controlled epidermal disruption with a topical drug formulation to reprogram skin stem cells and stimulate *de novo* hair follicle growth (neogenesis).

Follica competes with established pharmaceutical products (minoxidil, finasteride), surgical hair transplantation clinics, and other emerging biotech approaches targeting hair growth. Its primary differentiation is its aim to generate new follicles via a non-surgical procedure, a unique mechanism in the landscape. It must also contend with potential new entrants leveraging stem cell or gene therapy technologies.